«

»

Merck says new COVID-19 medication cuts the risk of hospitalization and death

In an effort to push back against the still-ongoing global COVID-19 pandemic, Merck, in partnership with Ridgeback Biotherapeutics, is touting the benefits of an investigational oral antiviral medication known as molnupiravir, saying it reduces the risk of hospitalization and death among people with mild-to-moderate cases of the coronavirus.

Read the full post at News Feed
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive